LEO Pharma reveals CEO succession plan

4 June 2019

Privately-held Danish medical dermatology specialist LEO Pharma today announced that Gitte Aabo will step down as president and chief executive after 27 years in the company, 11 of which were as CEO.

The board of directors has appointed Catherine Mazzacco as new president and CEO effective August 1, 2019. Ms Mazzacco is currently head of global commercial operations for GE Healthcare’s BioPharma division. Before that, she held numerous leadership positions at Abbott in the pharmaceutical, diagnostic and medical devices divisions.

LEO Pharma has embarked on an ambitious strategy towards 2025 and has during recent years succeeded in building a robust R&D pipeline and a significantly expanded global footprint. The next phase in the company’s strategy is to prepare the launch of a number of innovative therapies, and the board of directors and Gitte Aabo have jointly concluded that this is the right time to make a leadership change to continue the successful path of LEO Pharma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK